| Price | 63.00p on 19-12-2025 at 19:40:04 |
|---|---|
| Change | -2.50p -3.85% |
| Buy | 64.00p |
| Sell | 62.00p |
| Last Trade: | Sell 200,000.00 at 62.50p |
| Day's Volume: | 12,371,320 |
| Last Close: | 62.50p |
| Open: | 64.50p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 55.50p - 62.50p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £271.04m |
| VWAP: | 58.94583p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 200,000 | 62.50p | Ordinary |
16:41:53 - 19-Dec-25 |
| Sell* | 195,255 | 62.50p | Uncrossing Trade |
16:40:59 - 19-Dec-25 |
| Sell* | 250 | 62.55p | Ordinary |
16:27:52 - 19-Dec-25 |
| Sell* | 11,874 | 62.666p | Ordinary |
16:26:30 - 19-Dec-25 |
| Sell* | 7,405 | 62.75p | Ordinary |
16:25:55 - 19-Dec-25 |
| Sell* | 60 | 62.75p | Ordinary |
16:24:28 - 19-Dec-25 |
| Buy* | 483 | 63.4958p | Ordinary |
16:22:52 - 19-Dec-25 |
| Buy* | 6,765 | 63.499p | Ordinary |
16:19:29 - 19-Dec-25 |
| Buy* | 50,000 | 63.88p | Ordinary |
16:19:16 - 19-Dec-25 |
| Sell* | 1,750 | 62.50p | Ordinary |
16:17:22 - 19-Dec-25 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |
